Logo
x

Search

Subscribe Now

bridgebio

BridgeBio’s Beyonttra (Acoramidis) Gets the EU approval to Treat Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

BridgeBio’s Beyonttra (Acoramidis) Gets the EU approval to Treat Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

  • February 12, 2025
BridgeBio & Bayer Report the CHMP’s Positive Opinion of Beyonttra (Acoramidis) to Treat Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

BridgeBio & Bayer Report the CHMP’s Positive Opinion of Beyonttra (Acoramidis) to Treat Transthyretin Amyloidosis Cardiomyopathy (...

  • December 13, 2024
BridgeBio’s BBP-812 Gains the US FDA’s Regenerative Medicine Advanced Therapy Designation for Canavan Disease

BridgeBio’s BBP-812 Gains the US FDA’s Regenerative Medicine Advanced Therapy Designation for Canavan Disease

  • September 11, 2024
bridgebio Reports the Results for Acoramidis in P-III Trial for the Treatmnet of Transthyretin Amyloid Cardiomyopathy

bridgebio Reports the Results for Acoramidis in P-III Trial for the Treatmnet of Transthyretin Amyloid Cardiomyopathy

  • January 11, 2024
BridgeBio Collaborated with Resilience to Manufacture and Advance BBP-812 for Canavan Disease and BP-631 for Congenital Adrenal Hyperplasia

BridgeBio Collaborated with Resilience to Manufacture and Advance BBP-812 for Canavan Disease and BP-631 for Congenital Adrenal Hy...

  • October 5, 2023
BridgeBio Presents P-III Study (ATTRibute-CM) Results of Acoramidis for Transthyretin Amyloid Cardiomyopathy at ESC 2023

BridgeBio Presents P-III Study (ATTRibute-CM) Results of Acoramidis for Transthyretin Amyloid Cardiomyopathy at ESC 2023

  • August 28, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.